GLPwatch

Adlyxin

lixisenatide · sanofi

Last updated 2026-05-28

Adlyxin is a once-daily injectable diabetes medication containing the active ingredient lixisenatide, made by Sanofi. It is FDA-approved to improve blood sugar control in adults with type 2 diabetes. The label warns that it may increase the risk of thyroid tumors, including cancer, based on animal studies, and should not be used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

AI summary of the sources below.

Active ingredientlixisenatide
Manufacturersanofi
Routesubcutaneous injection
Approved indicationstype-2-diabetes

How Adlyxin connects

Top reported side effects

FAERS voluntary-report counts (2026Q1) — not incidence or causation.

Common questions

What is Adlyxin?
Adlyxin is a once-daily injectable diabetes medication containing the active ingredient lixisenatide, made by Sanofi. It is FDA-approved to improve blood sugar control in adults with type 2 diabetes. The label warns that it may increase the risk of thyroid tumors, including cancer, based on animal studies, and should not be used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
What is Adlyxin approved to treat?
Adlyxin is FDA-approved to treat type 2 diabetes.
Is there a shortage of Adlyxin right now?
We have no current FDA shortage record for lixisenatide (the active ingredient in Adlyxin).
What are the most-reported side effects of Adlyxin?
The most-reported adverse events for Adlyxin in the FDA's FAERS database are constipation, vomiting and injection site reaction. FAERS counts reflect voluntary reports and do not show how often a side effect actually occurs.
How is Adlyxin taken?
Adlyxin is given by subcutaneous injection.
Who makes Adlyxin?
Adlyxin is made by Sanofi.